Amorphous solid dispersion formulation
Patent Information
- Application Number
- HK62023084239
- Authority / Receiving Office
- HK · HK
- Patent Type
- Patents
- Current Assignee / Owner
- Priority Date
- 2020-12-30
- Filing Date
- 2023-12-18
- Publication Date
- 2026-09-04
- Estimated Expiration
- 2041-12-29
AI Technical Summary
In the prior art, cap-dependent endonuclease inhibitor compounds are difficult to develop into effective oral formulations due to their low water solubility, which limits their application in the treatment of influenza virus infection.
Amorphous solid dispersion technology is used to mix cap-dependent nuclease inhibitors or their pharmaceutically acceptable salts with pharmaceutically acceptable polymers such as PVP, PVP-VA, and Soluplus to form amorphous solid dispersions, thereby improving their solubility and bioavailability.
This invention achieves high solubility and bioavailability of cap-dependent endonuclease inhibitors, making them suitable for oral administration and effective treatment or prevention of influenza virus infection.
Abstract
Description
Technical Field
[0001] This invention discloses an amorphous solid dispersion (ASD) containing an anti-influenza compound and a method for preparing the same. Furthermore, this disclosure relates to a pharmaceutical composition containing the aforementioned amorphous solid dispersion and its use in treating influenza virus infection. Background Technology
[0002] Cap-dependent endonucleases (CLIs) are essential enzymes for influenza virus mRNA synthesis. CLI inhibitors have been found to be effective against both influenza A and B viruses, and several compounds have demonstrated effective antiviral activity against influenza viruses by inhibiting CLI activity. PCT Publication No. WO2019 / 144089 first disclosed a novel heterocyclic compound that can effectively inhibit CLI activity. However, one of the main limitations associated with this heterocyclic compound is its low water solubility. Due to its poor solubility, the challenge for this heterocyclic compound lies in how to develop it into an orally administered drug. Oral administration remains the most ideal dosage form because it is generally less expensive to produce, more preferred by patients and healthcare professionals, and has a higher overall compliance rate. Therefore, for a novel compound, finding a suitable oral formulation during the development phase is crucial, and this disclosure relates to the development of an oral solid dosage form of the heterocyclic compound disclosed in WO2019 / 144089. Summary of the Invention
[0003] This article provides an amorphous solid dispersion for oral administration comprising a cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof or a prodrug thereof, and a method for preparing the amorphous solid dispersion.
[0004] On the other hand, this article also provides an oral pharmaceutical composition comprising an amorphous solid dispersion of a cap-dependent endonuclease inhibitor or a pharmaceutically acceptable salt thereof or a prodrug thereof.
[0005] This article also provides a method for treating or preventing viral infections / diseases (e.g., influenza), comprising administering a therapeutically effective amount of the amorphous solid dispersion or oral pharmaceutical composition of this article to an individual in need. Detailed Implementation
[0006] To facilitate understanding of the invention described herein, several terms are defined below.
[0007] Generally, the nomenclature used herein and the laboratory procedures in organic chemistry, medicinal chemistry, and pharmacology described herein are well-known and commonly used nomenclature and laboratory procedures in this art. Unless otherwise defined, all technical and scientific terms used herein generally have the same meaning as commonly understood by one of ordinary skill in the art to which this invention pertains.
[0008] The term "about" refers to the acceptable range of error for a particular value measured by a person skilled in the art, which will depend in part on how the value was measured or determined, i.e., the limitations of the measurement system. As used herein, when referring to measurable or calculable values such as amount, duration, concentration, proportion, etc., variations of ±20%, ±10%, ±5%, ±1%, or ±0.1% relative to a particular value may be included, such variations being suitable for the disclosed methods.
[0009] As used in this article, the term "treatment" means the relief or elimination of a symptom, disease, or condition, or one or more symptoms associated with that symptom, disease, or condition; or the relief or eradication of the cause of the symptom, disease, or condition itself.
[0010] As used in this article, the term "prevention" refers to methods that include: delaying and / or preventing the onset of a disease, illness, or symptom and / or its accompanying symptoms; preventing an individual from contracting a disease, illness, or symptom; or reducing an individual's risk of contracting a disease, illness, or symptom.
[0011] As used herein, the terms “patient,” “individual,” or “subject” refer to human or non-human mammals. The terms “patient,” “individual,” or “subject” are used interchangeably herein; in one embodiment, the patient, individual, or subject is a human.
[0012] As used herein, the term "therapeutic effective amount" refers to an amount of active compound sufficient to prevent the development of one or more symptoms of the disease, ailment, or condition being treated, or to alleviate such one or more symptoms to a certain extent.
[0013] As used herein, the term "pharmaceutically acceptable carrier" refers to a material or medium that participates in carrying or transporting a compound useful to a patient into the patient's body, enabling it to perform its intended function without eliminating the biological activity of the administered compound. In one embodiment, a pharmaceutically acceptable carrier is a polymer.
[0014] As used herein, the terms “one or more” or “one or more” refer to one or more numbers (e.g., 2, 3, 4, 5, 6, 7 or more). The terms “one or more” or “one or more” are used interchangeably herein.
[0015] As used in this article, the term "halogen" refers to fluorine, chlorine, bromine, or iodine atoms.
[0016] The term "C" used in this article 1-4 "alkyl" or "C" 1-8 "Alkyl" refers to a branched or straight-chain monovalent saturated aliphatic hydrocarbon group containing 1 to 4 carbon atoms (e.g., 1 to 2 and 1 to 3) or 1 to 8 carbon atoms (e.g., 1 to 3, 1 to 4, 1 to 5, 1 to 6, and 1 to 7). Examples of alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, dibutyl, tributyl, pentyl, hexyl, heptyl, octyl, and similar groups.
[0017] The term "C" used in this article 1-4 "Alkoxy" refers to the group -OR a , where R a It is C 1-4 Alkyl group. C 1-4 Examples of alkoxy groups include methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy, isobutoxy, primary butoxy, tert-butoxy, and similar groups.
[0018] The term "C" used in this article 1-4 "Alkylamine" refers to -NHR b Group, wherein R b It is C 1-4 Alkyl, C 1-4 Examples of alkylamino groups include methylamino, ethylamino, isopropylamino, and similar groups.
[0019] As used herein, the term "carbocyclic ring" refers to a cyclic hydrocarbon group containing 3 to 16 member rings, including aromatic and non-aromatic carbocyclic rings.
[0020] As used herein, the term "aromatic carbocyclic ring" refers to an aromatic cyclic hydrocarbon group consisting of a single ring or having two or more rings, examples of which include benzene, naphthalene, and anthracene.
[0021] As used herein, the term "non-aromatic carbide ring" refers to a monocyclic saturated carbide ring or an unsaturated non-aromatic carbide ring composed of two or more rings. Non-aromatic carbide rings composed of two or more rings include fused cyclic groups, wherein the monocyclic non-aromatic carbide ring or the non-aromatic carbide ring composed of two or more rings is fused with the aforementioned "aromatic carbide ring". Furthermore, non-aromatic carbide rings composed of two or more rings also include bridged rings and spirocyclic systems.
[0022] The term "heterocyclic" as used in this article includes both aromatic and non-aromatic heterocyclic compounds.
[0023] As used herein, the term "aromatic heterocycle" refers to a monocyclic aromatic ring or an aromatic ring consisting of two or more rings containing one or more heteroatoms independently selected from oxygen, sulfur, and nitrogen atoms. Aromatic heterocycles consisting of two or more rings include fused cyclic groups, wherein the monocyclic aromatic heterocycle or the aromatic heterocycle consisting of two or more rings is fused with the aforementioned "aromatic carbide ring".
[0024] As used herein, the term "non-aromatic heterocycle" refers to a monocyclic or non-aromatic ring composed of two or more rings containing one or more heteroatoms independently selected from oxygen, sulfur, and nitrogen atoms. Non-aromatic heterocycles composed of two or more rings include fused cyclic groups, wherein the monocyclic or non-aromatic heterocycle is fused with the aforementioned "aromatic carbide ring," "non-aromatic carbide ring," and / or "aromatic heterocycle." Furthermore, non-aromatic heterocycles composed of two or more rings also include bridged rings and spirocyclic systems.
[0025] As used herein, the term "pharmaceutically acceptable salt" refers to a salt of the compounds described herein that, within a reliable medical evaluation, is suitable for contact with tissues of humans or lower animals without any undue toxicity, irritation, sensitization, etc. This includes pharmaceutically acceptable acid addition salts and base addition salts. They are effective for a particular purpose and are compatible with the chemical properties of the compounds described herein; see SM Birge et al., J. Pharm. Sci., 1977, 66, pp. 1-19.
[0026] As used herein, the term "prodrug" refers to a biologically reversible derivative of a drug molecule that can exert its desired pharmacological effect by releasing the active parent drug through enzymatic and / or chemical transformation. For example, the compounds described herein may form ester, amide, carbonate, carbonyl, or carbamate groups at the hydroxyl functional group as prodrug-forming moieties.
[0027] As used in this article, the term "amorphous" refers to a solid form of molecules and / or ions that are not crystalline and do not exhibit a well-defined X-ray diffraction pattern with sharp maxima.
[0028] As used herein, the term "solid dispersion" refers to a molecular dispersion of a compound, particularly a pharmaceutical substance, within a pharmaceutically acceptable carrier (e.g., a polymer). Solid dispersions generally refer to solid systems comprising at least two components, one of which is substantially uniformly dispersed among the other components. For example, a solid dispersion can be a dispersion of one or more active ingredients in a solid, inert carrier or matrix, prepared by methods such as spray drying, hot melt extrusion, fluidized bed drying, or lyophilization. The formation of solid dispersions provides a means to reduce particle size to near the molecular level.
[0029] As used herein, polyvinylpyrrolidone (PVP) refers to a polymer obtained by polymerizing N-vinyl-2-pyrrolidone. Examples of polyvinylpyrrolidone include PVP-K17, PVP-K25, PVP-K30, PVP-K40, PVP-K50, PVP-K60, PVP-K70, PVP-K80, PVP-K85, PVP-K90, PVP-K120, and similar substances.
[0030] As used herein, polyvinylpyrrolidone / vinyl acetate copolymer (also known as PVP-VA) refers to a copolymer of vinylpyrrolidone (also known as VP) and vinyl acetate (also known as VA) monomers. Examples of polyvinylpyrrolidone / vinyl acetate copolymers include PVP-VA64 and similar substances.
[0031] As used herein, methacrylic acid and methyl methacrylate copolymer refers to a copolymer derived from esters of acrylic acid and methacrylic acid. These are brand names for various methacrylic acid and methyl methacrylate copolymers. Examples of methacrylic acid and methyl methacrylate copolymers include... EPO, E100 RS100 RL100 L100 NE, NM, FS and similar substances.
[0032] As used herein, polyethylene glycol (PEG) refers to a polymer containing ethylene glycol monomer units of the formula -O-CH2-CH2-. Examples of polyethylene glycol include PEG1000, PEG1500, PEG2000, PEG2500, PEG3000, PEG3350, PEG3500, PEG4000, PEG5000, PEG6000, PEG8000, and similar substances.
[0033] As used herein, a polyoxyethylene-polyoxypropylene copolymer refers to a copolymer having both ethylene oxide monomer units and propylene oxide monomer units. Suitable polyoxyethylene-polyoxypropylene copolymers can have any chain length or molecular weight and may include branched chains. Their chain ends may have free hydroxyl groups or may have one or more hydroxyl groups etherified with lower alkyl or carboxyl groups. Polyoxyethylene-polyoxypropylene copolymers may also include other monomers copolymerized and forming part of the main chain. In some embodiments, the polyoxyethylene-polyoxypropylene copolymer may be a brand commercially available from BASF Performance Chemicals. It includes surfactants in the CTFA group: Poloxamer 108, 124, 188, 217, 237, 238, 288, 338, 407, 101, 105, 122, 123, 124, 181, 182, 183, 184, 212, 231, 282, 331, 401, 402, 185, 215, 234, 235, 284, 333, 334, 335, and 403.
[0034] As used herein, hydroxypropyl cellulose is also known as HPC. Examples of hydroxypropyl cellulose, depending on their average molecular weight, may include HPC-SSL, HPC-SL, HPC-L, HPC-M, HPC-H, and similar substances.
[0035] As used herein, hydroxypropyl methyl cellulose (HPMC) is also known as HPMC. Examples of hydroxypropyl methyl cellulose, depending on its viscosity, may include HPMC E3, HPMC E5, HPMC E6, HPMC E16, HPMC E30, HPMC E50 and HPMC E50Lv and similar substances.
[0036] As used herein, hydroxypropyl methylcellulose acetate succinate (also known as HPMCAS) refers to a mixture of acetic acid and monosuccinate of hydroxypropyl methylcellulose. In one specific embodiment, HPMCAS includes various types, such as HPMCAS-LF, HPMCAS-LG, HPMCAS-MF, HPMCAS-MG, HPMCAS-HF, HPMCAS-HG, and similar substances.
[0037] As used in this article, hydroxypropyl methylcellulose phthalate is also known as HPMCP. Examples of HPMCP include HPMCP HP-50, HPMCP HP-55, HPMCPHP-55S, and similar substances.
[0038] In one aspect, this disclosure relates to an amorphous solid dispersion comprising a cap-dependent endonuclease inhibitor for oral administration, wherein the cap-dependent endonuclease inhibitor is represented by formula (I) or a pharmaceutically acceptable salt thereof:
[0039]
[0040] Wherein, G is hydrogen or a prodrug group;
[0041] R1 is a halogen, deuterium, or C. 1-4 alkyl;
[0042] m is an integer from 1 to 9; and
[0043] An asterisk "*" represents a chiral center.
[0044] In one embodiment, R1 is a halogen, deuterium, or methyl; in another embodiment, R1 is a halogen or deuterium; and in yet another embodiment, R1 is fluorine or deuterium.
[0045] In one embodiment, equation (I) is derived from equation: The cyclic group represented is any of the following structures:
[0046] G is either hydrogen or -C(R2R2')-OC(=O)-O-R3; where R2 and R2' are each independently hydrogen or C. 1-4 Alkyl; and R3 is C 1-4 alkyl.
[0047] In one embodiment, m is 1, 2, 3, 4, 5, 6, 7, 8, or 9.
[0048] In one embodiment, G is selected from the group consisting of: hydrogen, -C(R2R2')-OC(=O)-R3, -C(R2R2')-OC(=O)-O-R3, -C(R2R2')-OC(=O)-C(R2R2')-NR4-C(=O)-OC(R2R2')-R3', -C(R2R2')-C(R2R2')-OC(=O)-R3, -C(R2R2')-R3', -C(=O)-R3, -C(=O)-NR3R4 and In this context, R2, R2', and R4 are each independently hydrogen or C. 1-8 Alkyl group; R3 and R3' are each independently C 1-8 Alkyl, C 3-10 carbonyl group or C 3-10 Heterocyclic group. In another embodiment, G is selected from hydrogen, -C(R2R2')-OC(=O)-R3, -C(R2R2')-OC(=O)-O-R3, -C(R2R2')-R3', -C(=O)-R3, and -C(=O)-NR3R4. In another embodiment, G is hydrogen or -C(R2R2')-OC(=O)-O-R3.
[0049] In one embodiment, each of R2, R2', and R4 is independently hydrogen or C. 1-4 Alkyl group. In another embodiment, each of R2, R2' and R4 is independently hydrogen, methyl, ethyl, propyl or isopropyl.
[0050] In one embodiment, R3 is C 1-4 Alkyl group. In another embodiment, R3 is methyl, ethyl, propyl, or heptyl.
[0051] In one embodiment, R3' is C 3-10 Carbocyclic group. In another embodiment, R3' is aryl. In another embodiment, R3' is phenyl.
[0052] In one embodiment, G is selected from the group consisting of: hydrogen,
[0053] In one embodiment, the compound of formula (I) is 1'-((11S)-7,8-difluoro-6H,11H-dibenzo[b,e]thiepin-11-yl)-1',2'-dihydro-5'-hydroxy-spiro[cyclopropane-1,3'-(3H)pyrido[1,2-b]pyridazine-4',6'-dione (1'-((11S)-7,8-difluoro-6H,11H-dibenzo[b,e]thiepin-11-yl)-1',2'-dihydro-5'-hydroxy-spiro[cyclopropane-1,3'-(3H)pyrido[1,2-b]pyridazine-4',6'-dione) or a pharmaceutically acceptable salt thereof.
[0054] In one embodiment, the compound of formula (I) is [1-((11S)-7,8-difluoro(6H,11H-dibenzo[c,f]thiepin-11-yl))-4,6-dioxospiro[1,2,3,9-tetrahydropyridino[1,2-e]pyrida zine-3,1'-cyclopropane]-5-yloxy]methyl methoxyformate or a pharmaceutically acceptable salt thereof.
[0055] In some embodiments, the compounds herein may be prepared according to the methods and procedures disclosed in PCT Publication No. WO2019 / 144089 or WO2021 / 239126, the entirety of which is incorporated herein by reference.
[0056] In one embodiment, this document provides an amorphous solid dispersion of a compound of formula (I) or a pharmaceutically acceptable salt thereof, which may further comprise a pharmaceutically acceptable polymer.
[0057] In another embodiment, this document discloses an amorphous solid dispersion comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable polymer thereof, wherein the compound of formula (I) or a pharmaceutically acceptable salt thereof is dispersed in a polymer matrix formed of a solid pharmaceutically acceptable polymer.
[0058] The pharmaceutically acceptable polymers used in the amorphous solid dispersions described in this article are water-soluble polymers. Suitable water-soluble polymers should serve as water-soluble carriers, imparting hydrophilicity to the active ingredient to improve its solubility and helping to maintain the solid dispersion in an amorphous state. Some common examples of water-soluble polymers include, but are not limited to, vinyl polymers and copolymers, polyvinylpyrrolidone (PVP), polyvinylpyrrolidone / vinylacetate copolymer (PVP-VA), polyvinyl alcohol (PVA), polyvinyl alcohol polyvinyl acetate copolymers, polyethylene polyvinyl alcohol copolymers, polyvinyl caprolactam and polyvinyl acetate, polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (also known as Soluplus), acrylate and methacrylate copolymers, and methacrylic acid and methyl methacrylate copolymer (e.g.). Polyethylene glycol (PEG), polyoxyethylene-polyoxypropylene copolymers (also known as poloxamers), cellulose derivatives, hydroxypropyl methyl cellulose acetate (HPMCA), hydroxypropyl methyl cellulose (HPMC), hydroxypropyl cellulose (HPC), methyl cellulose, hydroxyethyl methyl cellulose, hydroxyethyl cellulose, hydroxyethyl cellulose acetate, hydroxyethyl ethyl cellulose, hydroxypropyl methyl cellulose acetate succinate (HPMCAS), hydroxypropyl methyl cellulose phthalate (HPMCP), Kollidon SR (80% polyvinyl acetate and 20% polyvinylpyrrolidone), carboxymethyl ethyl cellulose. cellulose (CMEC), cellulose acetate phthalate (CAP), cellulose acetate succinate (CAS), hydroxypropyl methylcellulose acetate phthalate (HPMCAP), cellulose acetate trimellitate (CAT), hydroxypropyl methylcellulose acetate trimellitate (HPMCAT), carboxymethylcellulose acetate butyrate (CMCAB), or combinations thereof.
[0059] In one embodiment, the pharmaceutically acceptable polymer is a polyvinylpyrrolidone / vinyl acetate copolymer (PVP-VA), a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer (Soluplus), a copolymer of methacrylic acid and methyl methacrylate, hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose acetate succinate (HPMCAS), hydroxypropyl methylcellulose phthalate (HPMCP), polyethylene glycol (PEG), or Kollidon SR. In another embodiment, the polyvinylpyrrolidone / vinyl acetate copolymer is PVP-VA64; HPC is HPC-SSL; HPMCAS is HPMCAS-MG or HPMCAS-HG; HPMCP is HPMCP HP-55; PEG is PEG3350; and the copolymer of methacrylic acid and methyl methacrylate is... EPO.
[0060] In one embodiment, the pharmaceutically acceptable polymer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, hydroxypropyl cellulose (HPC), or hydroxypropyl methylcellulose acetate succinate (HPMCAS). In another embodiment, the pharmaceutically acceptable polymer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, HPC-SSL, HPMCAS-MG, or HPMCAS-HG. In yet another embodiment, the pharmaceutically acceptable polymer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or HPC-SSL.
[0061] In one embodiment, the pharmaceutically acceptable polymer is a polyvinylcaprolactam-polyvinyl acetate-polyethylene glycol graft copolymer. In another embodiment, the pharmaceutically acceptable polymer is HPC-SSL.
[0062] In one embodiment, an amorphous solid dispersion comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable polymer thereof, wherein the weight ratio of the compound of formula (I) or a pharmaceutically acceptable salt thereof to the pharmaceutically acceptable polymer is approximately 4:1, 3.5:1, 3:1, 2:5:1, 2:1, 1.5:1, 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 1:4, 1:4.5, 1:5, 1:5.5, 1:6, 1:6.5, 1:7, 1:7.5, 1:8, 1:8.5, 1:9, 1:9.5 or 1:10. In another embodiment, the weight ratio of the compound of formula (I) or its pharmaceutically acceptable salt to the pharmaceutically acceptable polymer is within the range between any two of the above ratios, for example, 2:1 to 1:7, 1:1 to 1:7, 1:1 to 1:6.5, 1:1 to 1:6, 1:1 to 1:5.5, 1:1 to 1:5, 1:1 to 1:4.5, 1:1 to 1:4, 1:1 to 1:3.5, 1:1 to 1:3, 1:1 to 1:2.5, 1:1 to 1:2, 1:1.5 to 1:7, 1:1.5 to 1:6.5, 1:1.5 to 1:6, 1:1.5 to 1:5.5, 1:1.5 to 1:5, 1:1.5 to 1:4.5, 1:1.5 to 1:4, 1:1.5 to 1:3.5, 1:1.5 to 1:3, 1:2 to 1:5, 1:2 to 1:4 or 1:2 to 1:3.
[0063] In one embodiment, the weight percentage of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the amorphous solid dispersion is generally 10 to 60%, 10 to 55%, 10 to 50%, 10 to 45%, 10 to 40%, 15 to 60%, 15 to 55%, 15 to 50%, 15 to 45%, or 15 to 40%, for example, the weight percentage of the compound of formula (I) or a pharmaceutically acceptable salt thereof in the amorphous solid dispersion is about 15%, 25%, 33%, 40%, or 50%. In one embodiment, the amorphous solid dispersion of the compound of formula (I) or a pharmaceutically acceptable salt thereof comprises 10 to 60% w / w (weight percentage) of the compound of formula (I) or a pharmaceutically acceptable salt thereof and 40 to 90% w / w (weight percentage) of a pharmaceutically acceptable polymer. In another embodiment, the amorphous solid dispersion of the compound of formula (I) or a pharmaceutically acceptable salt thereof comprises 15 to 50% w / w (weight percentage) of the compound of formula (I) or a pharmaceutically acceptable salt thereof and 50 to 85% w / w (weight percentage) of a pharmaceutically acceptable polymer.
[0064] On the other hand, the amorphous solid dispersions described herein can be administered orally to individuals in need (e.g., humans) to treat or prevent infectious diseases such as influenza.
[0065] In one embodiment, the amorphous solid dispersion described herein can be prepared by methods known in the art, such as spray drying, hot melt extrusion, fluidized bed or freeze drying. In one embodiment, the amorphous solid dispersion is prepared by spray drying.
[0066] In one embodiment, the amorphous solid dispersion of this invention is prepared by dissolving a compound of formula (I) or a pharmaceutically acceptable salt thereof in a sufficient amount of organic solvent, and mixing the resulting solution with a solution containing a pharmaceutically acceptable polymer. This produces a spray solution. The solvent can then be evaporated, leaving the drug dispersed / dissolved in the matrix. Any organic solvent capable of dissolving or dispersing a compound of formula (I) or a pharmaceutically acceptable salt thereof, as well as the aforementioned pharmaceutically acceptable polymer, may be used in this disclosure. Examples of organic solvents include low carbon alcohols (e.g., methanol, ethanol, propanol, or isopropanol), ketones (e.g., acetone, butanone, or methyl isobutyl ketone), haloalkanes (e.g., dichloromethane, chloroform, or carbon tetrachloride), acetic acid, ethyl acetate, N,N-dimethylformamide, DMSO, tetrahydrofuran, or mixtures thereof.
[0067] In one embodiment, the preparation of the amorphous solid dispersion comprises the following steps: (i) dissolving a compound of formula (I) or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable polymer thereof in a solvent, and (ii) drying the solution obtained in step (i).
[0068] In one embodiment, step (i) includes: dissolving a compound of formula (I) or a pharmaceutically acceptable salt thereof in a sufficient amount of organic solvent; dissolving a pharmaceutically acceptable polymer in the solvent; and mixing the two solutions.
[0069] In one embodiment, step (ii) includes spray drying; in another embodiment, step (ii) includes spray drying in combination with a fluidized bed; and in yet another specific embodiment, step (ii) includes evaporating the solvent using a rotary evaporator.
[0070] The term "spray drying" is used routinely and widely to refer to the process of breaking a liquid mixture into small droplets (atomization) and rapidly removing the solvent from the liquid mixture in a spray drying device (such as a nozzle), where a strong driving force evaporates the solvent from the droplets. In a typical spray drying process, the feed liquid can be a solution, slurry, emulsion, gel, or paste, as long as it is pumpable and capable of being atomized.
[0071] The amorphous solid dispersions described in this paper were characterized by polarized light microscopy (PLM), X-ray powder diffraction (XRPD), thermogravimetric analysis (TGA), and particle size distribution analysis (PSD). Furthermore, differential calorimetry (DSC) was used to analyze the thermochemical properties of the amorphous solid dispersions. The results showed that the amorphous solid dispersions of compound (I) or its pharmaceutically acceptable salts exhibited only one glass transition temperature and no endothermic peaks (melting peaks), confirming that the solid dispersions of compound (I) or its pharmaceutically acceptable salts are amorphous. The obtained amorphous solid dispersions can be formulated into pharmaceutical compositions with high bioavailability.
[0072] On the other hand, this document also relates to a pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) in the form of an amorphous solid dispersion or a pharmaceutically acceptable salt thereof. In one embodiment, the pharmaceutical composition comprising the amorphous solid dispersion described herein may be an oral or inhaled formulation as a capsule, tablet, powder, pellet, granule, suspension, or inhaler. The pharmaceutical composition form used may be coated, for example, using an enteric coating. The pharmaceutical composition may be administered orally or inhaled in single or multiple doses.
[0073] In one embodiment, the pharmaceutical composition comprises the amorphous solid dispersion of this disclosure and optionally one or more pharmaceutically acceptable excipients that are non-biologically active and do not react with the active compound. Examples of pharmaceutically acceptable excipients include binders, flow aids, plasticizers, solubilizers, stabilizers, antioxidants, diluents, surfactants, disintegrants, lubricants, fillers, wetting agents, sweeteners, colorants, flavoring agents, or mixtures thereof. In some specific embodiments, when the pharmaceutical composition is a powder, the pharmaceutically acceptable excipient is a finely ground solid that can be mixed with the finely ground active ingredient. In some embodiments, when the pharmaceutical composition is formulated into tablets, the active ingredient (i.e., the amorphous solid dispersion) can be mixed with the pharmaceutically acceptable excipient in a suitable proportion and compressed into the desired shape and size. In some embodiments, when the pharmaceutical composition is in capsule form, it can be various types of capsules known in the art, for example, capsules made of hydroxypropyl methylcellulose or gelatin can be used.
[0074] This disclosure will be further understood through the following non-limiting examples.
[0075] Example 1: Preparation of methyl methoxyformate [1-((11S)-7,8-difluoro(6H,11H-dibenzo[c,f]thiophene-11-yl))-4,6-dioxospiro[1,2,3,9-tetrahydropyrido[1,2-e]pyridazine-3,1'-cyclopropane]-5-yloxy]methoxyformate (compound A)
[0076] Methyl methoxyformate [1-((11S)-7,8-difluoro(6H,11H-dibenzo[c,f]thiophene-11-yl))-4,6-dioxospiro[1,2,3,9-tetrahydropyrido[1,2-e]pyridazine-3,1'-cyclopropane]-5-oxy]methoxyformate (compound A) was prepared according to the synthetic routes and schemes reported by Hsu et al. in WO2019 / 144089 or Chen et al. in WO2021 / 239126. The mass spectrometry (MS) and nuclear magnetic resonance (NMR) data of compound A are as follows: MS: m / z 541.0 (M + +1); 1 H NMR(CDCl3)δ7.31(d,1H),7.06-7.00(m,4H),6.85-6.84(m,1H),6.73(d,1H),6.03(d,1H),5.96(d,1H),5.80(d,1H),5.49(d,1 H),5.15(s,1H),4.13(d,1H),4.05(d,1H),3.87(s,3H),2.91(d,1H),1.95-1.90(m,1H),1.49-1.48(m,1H),0.88-0.76(m,2H).
[0077] Example 2: Preparation of amorphous solid dispersions
[0078] The amorphous solid dispersions disclosed herein are prepared by spray drying methods known in the art, for example, see Singh et al., Advanced Drug Delivery Reviews, 2016, 100, pp. 27-50. Different pharmaceutically acceptable polymers, such as PVP-VA64, Soluplus, HPMCAS-MG, HPMCAS-HG, etc., are used. EPO, HPC-SSL, HPMCP HP-55, Kollidon SR, and PEG3350 were used to prepare the amorphous solid dispersions of this disclosure. A 4M8-Trix spray dryer was used to prepare the amorphous solid dispersions. The spray drying concentration of compound A was set to 25 mg / mL. Compound A was mixed with different pharmaceutically acceptable polymers in varying proportions and dissolved in a solvent (e.g., acetone) in a glass vial to provide a feed solution. The resulting feed solution was sprayed into a chamber as a fine spray through a nozzle, where the solvent rapidly evaporated to produce particles containing compound A and the corresponding polymers. The resulting spray-dried powder was further dried in a static dryer to remove residual solvent.
[0079] Example 3: Dissolution Assessment
[0080] A specific amount of compound A (approximately 6 mg) and an amorphous solid dispersion (containing approximately 6 mg of compound A) were weighed into separate 8 mL bottles. 6 mL of FaSSIF (fasting-state simulated intestinal fluid) was added, with a target concentration of 1.0 mg / mL. The suspension was then stirred in a hot mixer at 37°C and 600 rpm. At predetermined time intervals (e.g., 5 minutes), 200 μL of the suspension was collected and centrifuged at 14,000 rpm for 4 minutes. 100 μL of the supernatant was then diluted with 500 μL of acetonitrile to prevent precipitation and analyzed by HPLC.
[0081] The preparation steps for FaSSIF are as follows: 1) Place 0.1024 g of sodium hydroxide, 0.7518 g of anhydrous sodium dihydrogen phosphate, and 1.5470 g of sodium chloride in a 250 mL flask, add approximately 225 mL of water, and adjust the pH to 6.5 with 1 N sodium hydroxide or 1 N hydrochloric acid. Make up to a volume of 250 mL with pure water. 2) Place 0.4480 g of SIF Powder Original and 100 mL of buffer solution (from step 1) in a 200 mL flask and dissolve. Make up to a volume of water and mix thoroughly.
[0082] Table 1 lists the solubility of compound A and its amorphous solid dispersion in FaSSIF at 5 minutes and 15 minutes.
[0083] Table 1
[0084]
[0085] Example 4: Stability Study of Amorphous Solid Dispersions
[0086] Amorphous solid dispersions were stored at 4°C (closed state), 20°C / 60%RH (closed and open state), or 40°C / 75%RH (closed and open state). After 10 days or 4 weeks, samples were observed with a camera, characterized using XRPD, and their purity and kinetic solubility were analyzed by HPLC. All samples stored under closed conditions were placed in clear glass vials with gaskets and screw caps, while all samples stored under open conditions were placed in open clear glass vials with caps covered at the necks with aluminum foil with pinholes to prevent cross-contamination.
[0087] Table 2 shows the total impurity levels (i.e., TRS%; total related substances) of ASDs after stability studies. The sample numbers in Table 2 correspond to the sample numbers in Table 1.
[0088] Table 2
[0089]
[0090] Other implementation methods
[0091] All features disclosed in the specification can be combined in any way. Various features disclosed in the specification can be replaced by features that serve the same, equivalent, or similar purpose. Therefore, unless otherwise stated, the disclosed features are merely examples of a series of equivalent or similar features. Through the above description, those skilled in the art can readily identify the main features of the invention, and various changes and modifications can be made to the invention without departing from its spirit and scope to adapt it to various applications and conditions. Therefore, other embodiments are also within the scope of the appended claims.
Claims
1. An amorphous solid dispersion comprising compound A or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable polymer; in, The compound A is [1-((11)] S )-7,8-difluoro(6 H ,11 H -dibenzo[ c,f ]Thiophene-11-yl))-4,6-dioxospiro[1,2,3,9-tetrahydropyrido[1,2- e Methyl pyridazine-3,1'-cyclopropane]-5-yloxy]methoxyformate; The pharmaceutically acceptable polymer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, HPC-SSL, or hydroxypropyl methylcellulose acetate succinate (HPMCAS), and The weight ratio of compound A or its pharmaceutically acceptable salt to the pharmaceutically acceptable polymer is in the range of 1:1 to 1:
3.
2. The amorphous solid dispersion as described in claim 1, wherein, The pharmaceutically acceptable polymer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer or HPC-SSL.
3. The amorphous solid dispersion as described in claim 1, wherein, The pharmaceutically acceptable polymer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer, HPC-SSL, HPMCAS-MG, or HPMCAS-HG.
4. The amorphous solid dispersion as described in claim 1, wherein, The weight ratio of compound A or its pharmaceutically acceptable salt to the pharmaceutically acceptable polymer is in the range of 1:1 to 1:2.
5.
5. The amorphous solid dispersion as described in claim 1, wherein, The weight ratio of compound A or its pharmaceutically acceptable salt to the pharmaceutically acceptable polymer is in the range of 1:1 to 1:
2.
6. The amorphous solid dispersion as described in claim 5, wherein, The pharmaceutically acceptable polymer is a polyvinyl caprolactam-polyvinyl acetate-polyethylene glycol graft copolymer.
7. The amorphous solid dispersion as described in claim 5, wherein, The pharmaceutically acceptable polymer is HPC-SSL.
8. The amorphous solid dispersion according to any one of claims 1-7, wherein, The weight ratio of compound A or its pharmaceutically acceptable salt to the pharmaceutically acceptable polymer is in the range of 1:1 to 1:1.
5.
9. A pharmaceutical composition comprising an amorphous solid dispersion as described in any one of claims 1-8 and one or more pharmaceutically acceptable excipients.
10. The pharmaceutical composition of claim 9, wherein, The pharmaceutical composition is in the form of capsules, tablets, powders, pills, suspensions, granules, or inhalers.
11. The pharmaceutical composition of claim 9, wherein, The pharmaceutically acceptable excipients are selected from binders, gliding agents, plasticizers, solubilizers, stabilizers, antioxidants, surfactants, disintegrants, lubricants, fillers, wetting agents, sweeteners, colorants, flavoring agents, and mixtures thereof.
